

UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF LOUISIANA

In Re: TAXOTERE (DOCETAXEL)  
PRODUCTS LIABILITY LITIGATION

MDL NO. 2740

SECTION "H" (5)

THIS DOCUMENT RELATES TO:  
Barbara Earnest, Case No. 2:16-cv-17144

**MEMORANDUM IN SUPPORT OF PLAINTIFFS' MOTION *IN LIMINE* TO  
PRECLUDE DEFENSE COUNSEL FROM COMMENTING ON OR DISCUSSING  
CERTAIN MATTERS IN THE PRESENCE OF THE JURY OR POTENTIAL JURORS  
(Motion *in Limine* No. 8)**

**I. INTRODUCTION**

Plaintiff respectfully request that this Court preclude counsel for Defendants and all witnesses from mentioning, discussing, or commenting on certain irrelevant and unfairly prejudicial matters, directly or indirectly, in the presence of the jury or potential jurors, the matters specifically listed herein. All of the identified matters are wholly irrelevant to the claims at issue in this case, as they are of no consequence to determining any legal claim at issue in trial.

Further, any discussion of these matters would serve no purpose other than to confuse or mislead the jury, creating a very real danger of unfair prejudice and that the jury will improperly decide the case on emotion or other factors apart from the proper evidence and the law as instructed by the Court. Permitting counsel and witnesses to interject these improper statements or comment on these matters, thus requiring Plaintiff's counsel to repeatedly object in the presence of the jury, would only serve to draw attention to them and exacerbate the unfair prejudicial impact on Plaintiff.

**II. ARGUMENT**

In light of the obvious irrelevance of these matters, and the unfair prejudice that is likely to result to Plaintiff if they are raised in the presence of the jury or potential jurors, an Order *in*

*limine* directing counsel to refrain from discussing, commenting on, or referencing the following matters in the presence of the jury is both necessary and appropriate:

1. **Any comments, references, testimony, or evidence regarding settlement negotiations, or any conduct or statements made in reference or during settlement negotiations.** *See* Fed. R. Evid. 408. In fact, the need for this prohibition is so obvious that parties often agree to the exclusion of any testimony, reference, or inference regarding settlement negotiations. *See, e.g., In re Xarelto (Rivaroxaban) Products Liab. Litig.*, MDL 2592 (E.D. La. Apr. 18, 2017); *In re Chinese Manufactured Drywall Prods. Liab. Litig.*, MDL No. 2047, 2012 U.S. Dist. LEXIS 166442, at \*28 (E.D. La. Nov. 21, 2012); *Dedrick v. Merck & Co., Inc. (In re Vioxx)*, No. 2:05-md-01657, slip op. at ¶ 3y (E.D. La. Nov. 22, 2006); *Terry v. McNeil-PPC, Inc. (In re Tylenol (Acetaminophen) Mktg., Sales Practices & Prods. Liab. Litig.)*, No. 2:12-cv-07263, 2016 U.S. Dist. LEXIS 72774, at \*4-6 (E.D. Pa. June 3, 2016); *In re Yasmin & Yaz (Drospirenone) Mktg., Sales Practices and Prods. Liab. Litig.*, No. 3:09-md-2100, 2011 U.S. Dist. LEXIS 147935, at \*42 (S.D. Ill. Dec. 22, 2011).

2. **Any reference, suggestion, or inference regarding the number of lawyers representing Plaintiffs; the fact that some of Plaintiffs' lawyers may reside or practice outside of Louisiana; the financial status or resources of Plaintiffs' lawyers; the means of travel of accommodations of Plaintiffs' lawyers; and/or the fact that some of Plaintiffs' lawyers may have represented other clients in other pharmaceutical cases or specializations, or the topics involved in those other matters.** Defendant should not be allowed to lead the jury astray with such irrelevant comments, suggestions, or references, as such are wholly unrelated to and have no bearing on any fact of consequence in determining this case. Fed. R. Evid. 401, 402. Further, any such testimony would be highly and unfairly prejudicial, and is calculated to do nothing more than inflame jurors and play on their biases about lawyers or the alleged need for tort reform. Fed. R.

Evid. 403. In fact, it is well-established that these types of suggestions, references, and comments are irrelevant to the issues of the case and unduly prejudicial, and thus excluded at trial. *See, e.g., Dedrick v. Merck & Co., Inc. (In re Vioxx)*, No. 2:05-md-01657, slip op., at ¶ 31 (E.D. La. Nov. 22, 2006) (excluding “[a]ny comment or inference that Plaintiff’s attorneys and their law firm primarily represent plaintiffs in lawsuits or specialize in personal injury or product liability litigation.”); *In re Tylenol (Acetaminophen) Mktg., Sales Practices & Prods. Liab. Litig.*, No. 2:12-cv-07263, 2016 U.S. Dist. LEXIS 72774, at \*16-19 (E.D. Pa. June 3, 2016) (excluding evidence about the financial status or resources of the plaintiff’s attorneys, their other businesses or cases, and their travel or the travel of their witnesses by private jet, holding that “[t]his evidence is irrelevant to the issues of this case and would be unduly prejudicial.”); *Dixon v. Home Depot U.S.A.*, No. 13-cv-2776, 2015 U.S. Dist. LEXIS 79070, at \*1-2 (W.D. La. June 10, 2015) (precluding references to Plaintiff’s counsel’s representation of clients in other cases involving similar products and their motives in doing so); *Mack v. R.J. Reynolds Tobacco Co.*, 2010 Fla Cir. LEXIS 2214, at \*4 (Fla. 8th Cir. Ct. 2010) (“No reference to any specific law firm or attorney shall be made by [] counsel or witness.”); *United States Fire Ins. Co. v. Sonitrol Corp.*, 2010 Colo. Dist. LEXIS 593, \*5-7 (Colo Dist. Ct. 2010) (granting motion *in limine* to exclude evidence concerning legal representation, including the number of attorneys representing the party’s behalf); *De Boer Structures (U.S.A.) v. Shaffer Tent & Awning Co.*, 2002 U.S. Dist. LEXIS 23816, \*10 (S.D. Ohio Oct. 29, 2002) (Sargus, J.) (precluding “testimony or evidence at any stage of the trial regarding the size, resources or location” of a party’s law firm).

3. **Any comments, references, attempts to introduce testimony or evidence about, or introducing testimony or evidence about, an alleged “Litigation Crisis,” “Lawsuit Crisis,” “Lawsuit Abuse,” “Lawyer-Driven Science” or “Lawyer-Driven Litigation.”** Defendant may

attempt to present argument or evidence suggesting that this lawsuit or litigation as a whole and the science involved is lawyer-driven, fabricated, or exaggerated by counsel who make money through product liability lawsuits. In fact, Plaintiff has good reason to believe that Defense Counsel will seek to comment on these matters at trial based on, among other things, similar comments made by Defense Counsel at hearings.<sup>1</sup> Not only is such testimony unrelated to any fact of consequence in this action, thus rendering such testimony irrelevant and inadmissible pursuant to Rules 401 and 402, but any suggestions to this effect would improperly and unjustifiably focus the trial on Counsel's behavior, thus inappropriately appealing to any bias jurors may have against the legal profession and resulting in unfair prejudice to Plaintiff. Fed. R. Evid. 403. Statements regarding the motives for filing suit, or suggestions that there is a lawsuit/litigation crisis or that lawsuits are driven by lawyers, have been excluded by numerous courts. *See, e.g., In re Xarelto (Rivaroxaban) Products Liab. Litig.*, MDL 2592 (E.D. La. Apr. 18, 2017) (sustaining motion filed by Plaintiff); *Barnett v. Merck & Co., Inc. (In re Vioxx)*, No. 3:09-cv-10012, slip op., ¶3k (E.D. La. Nov. 18, 2011) (precluding “[a]ny reference to ‘litigation crisis,’ ‘lawsuit crisis,’ ‘lawsuit abuse,’ or any other similar term or phrase”); *Dedrick v. Merck & Co., Inc. (In re Vioxx)*, No. 2:05-md-01657, slip op., at ¶3k (E.D. La. Nov. 22, 2006) (precluding “[a]ny mention of the purported ‘litigation crisis,’ ‘lawsuit crisis,’ ‘lawsuit abuse,’ or similar terms or phrases”); *Dixon v. Home Depot U.S.A.*, No. 13-cv-27765, 2015 U.S. Dist. LEXIS 79070, at \*1-2 (W.D. La. June 10, 2015) (excluding any references to the “alleged motives of Plaintiff’s counsel in prosecuting this or other similar lawsuits”); *Cona v. Merck & Co., Inc.*, No. ATL-3553-05, slip op. at ¶t (N.J. Super. Ct. Mar. 28, 2006) (same).

---

<sup>1</sup> *See, e.g.*, Trans. of March 27, 2019 Discovery Hearing before Mag. Judge North at 28 (“litigation-driven” science comments presented by counsel for Sanofi).

4. **Any statement, suggestion, or comments before the jury venire, in opening statement, or in closing argument regarding the potential adverse effect that could result if the jury returns a verdict in favor of Plaintiff, including but not limited to suggestions that a verdict for the Plaintiff will adversely impact pharmaceutical companies' incentive and/or ability to develop new medications, the ability of any member of the jury to purchase or receive medications in the future, the cost of medication, the availability of pharmaceutical drugs to individuals or industries in the United States or worldwide, the stock price of Defendant or any other publicly-traded manufacturer, the cost of purchasing or maintaining health insurance, or the cost of pharmaceutical drugs to the public.** Such arguments are “inherently prejudicial and urge the jury to render its verdict based on passion and prejudice.” *Sjöstrand v. Ohio State Univ.*, 2014 U.S. Dist. LEXIS 125163, at \*22-23 (S.D. Ohio Sept. 8, 2014). As such, numerous courts have precluded such evidence of the potential adverse effects of a Plaintiffs' verdict under Federal Rules of Evidence 401-403. *See, e.g., In re Xarelto (Rivaroxaban) Products Liab. Litig.*, MDL 2592 (E.D. La. Apr. 18, 2017); *Barnett v. Merck & Co., Inc. (In re Vioxx)*, No. 3:09-cv-10012, slip op., at ¶¶ 3(a) (b), (c), (e), (f) (E.D. La. Nov. 18, 2011); *Dedrick v. Merck & Co., Inc. (In re Vioxx)*, No. 2:05-md-01657, slip op., ¶¶ 3(a), (b), (c), (e), (f) (E.D. La. Nov. 22, 2006); *Plunkett v. Merck & Co., Inc. (In re Vioxx)*, No. 2:05-md-04046, slip op., at ¶¶ 3 (a), (b), (c), (e), (f) (E.D. La. Nov. 18, 2005); *Gray v. Energy XXI Gom LLC*, Case No. 12-165, 2013 U.S. Dist. LEXIS 109459 (M.D. La. Aug. 5, 2013) (ruling that “[n]o statement, reference, or appeal may be made to the jury that they serve as the ‘conscience of the community,’ or that the jury should render a verdict that will make the community proud.”); *Powell v. Geekie*, No. 5:09-cv-188, 2010 U.S. Dist. LEXIS 90831, at \*5 (M.D. Ga. Sept. 1, 2010). Indeed, the Fifth Circuit has

condemned such appeals to “community conscience” as improper. *See Westbrook v. General Tire & Rubber Co.*, 754 F.2d 1233, 1238-39 (5th Cir. 1985).

**5. Any comments, references, statements, or testimony regarding Professional Associations, Trial Strategies, and Educational Seminars and Materials, including but not limited to, Mass Torts Made Perfect (MTMP), the American Association for Justice (AAJ), The Reptile, the Jerry Spence Trial College, or any other books, seminars, and educational materials for plaintiff attorneys.** Evidence concerning the training and education available to Plaintiff attorneys is not related in any way to the facts of consequence in this case, and it will have no tendency to make a fact that is of consequence in this case more or less probable than it would be without the evidence, and is thus irrelevant and inadmissible. *See Fed. R. Evid. 401; Fed. R. Evid. 402.* Further, such evidence is calculated to do nothing more than inflame the jurors and play on their biases, and would be highly and unfairly prejudicial to Plaintiffs. *See Fed. R. Evid. 403.* In today’s world, public suspicion and even disapproval of the professional conduct of plaintiffs’ attorneys is not uncommon, and evidence regarding their training and educational opportunities easily could play into those prevailing notions. In fact, both courts and defendant pharmaceutical companies have acknowledged the need to preclude this type of evidence. *See, e.g., In re Xarelto (Rivaroxaban) Products Liab. Litig.*, MDL 2592 (E.D. La. Apr. 18, 2017) (sustaining this same motion filed by Plaintiff); *In re Tylenol (Acetaminophen) Mktg., Sales Practices & Prods. Liab. Litig.*, No. 2:12-cv-07263, 2016 U.S. Dist. LEXIS 72774, at \*19 (E.D. Pa. June 23, 2016).

**6. Any comment or reference regarding the compensation paid to any of Plaintiff’s experts in cases other than the case being tried. Alternatively, if such questioning is permitted, Plaintiff should be allowed to elicit testimony regarding the number of cases involved in the other litigation, the issues involved and the impact of the experts’ testimony**

**on those cases.** Federal Rule of Civil Procedure 26(a)(2)(B)(vi) requires that a party shall disclose “the compensation to be paid for the [expert’s] study and testimony in the case.” There is no question that cross-examination of an expert regarding compensation received to show bias is “entirely proper.” *Collins v. Wayne Corp.*, 621 F.2d 777, 784 (5th Cir. 1980). However, in complex litigation, delving into compensation received by an expert under the guise of seeking impeachment evidence both at the discovery and trial stages “should be tightly controlled by the trial court and limited to its purpose.” *Cary Oil Co. v. MG Ref. & Mktg., Inc.*, 257 F. Supp. 2d 751, 757 (S.D.N.Y. 2003), quoting *Wroblewski v. deLara*, 353 Md. 509, 727 A. 2d 930, 938 (1999). Unless an expert’s opinion “has materially changed in such a way so as to raise a reasonable suspicion that the compensation paid to such expert may have affected the subsequent opinion,” the inquiry should be limited. *Id.* Plaintiff submits that delving into compensation received by Plaintiff’s experts from other cases will not assist the trier of fact in determining witness bias and such inquiry should be prohibited. Alternatively, should the Court allow such inquiry, Plaintiff should be afforded an opportunity to put the amount of compensation received by her experts into context and be allowed to elicit testimony regarding the issues involved in the other litigation and the positive impact of the experts’ testimony on those cases.

7. **Any comment or reference regarding how much an expert is being paid in this litigation, which payments often include work benefitting all plaintiffs in this MDL.** Plaintiff takes no issue with cross-examination related to compensation received by the expert for case specific deposition and trial preparation. But if defendants are permitted to delve into the *total* amount of compensation received by an expert, Plaintiff should be entitled to put the compensation amount into context by eliciting testimony regarding the 11,000 lawsuits pending in this MDL and the benefit of the expert’s work on those lawsuits. As previously noted, cross-examination of an

expert regarding compensation paid to him for his work on a case is “entirely proper.” *Collins v. Wayne Corp.*, 621 F.2d at 784. However, when the compensation paid to the expert is not for a single case, but for many cases, cross-examination regarding total compensation received lacks context. To put the amount of compensation received into proper context, the experts should be allowed to break out their compensation into case specific work, primarily case specific deposition and trial preparation. Alternatively, should cross-examination regarding total compensation paid to an expert be permitted, Plaintiff should be permitted to elicit testimony regarding the number of lawsuits in this MDL and the benefit of the expert’s work on those lawsuits.

### CONCLUSION

For the foregoing reasons, and in the interests of justice and a fair trial, Plaintiff respectfully requests that the Court preclude Counsel from discussing or commenting on the identified matters at trial in the presence of the jury or potential jurors, and that Counsel be directed to advise any corporate representatives and witnesses to avoid discussing or commenting on the identified matters at trial.

Dated: July 16, 2019

Respectfully submitted,

/s/ Darin L. Schanker  
Darin L. Schanker  
Bachus & Schanker, LLC  
1899 Wynkoop Street, Suite 700  
Denver, CO 80202  
Phone: (303) 893-9800  
Fax: (303) 893-9900  
[dschanker@coloradolaw.net](mailto:dschanker@coloradolaw.net)

/s/ Rand P. Nolen  
Rand P. Nolen  
Fleming, Nolen & Jez, L.L.P.  
2800 Post Oak Blvd., Suite 4000  
Houston, TX 77056  
Phone: (713) 621-7944  
Fax: (713) 621-9638  
[rand\\_nolen@flaming-law.com](mailto:rand_nolen@flaming-law.com)

*Counsel for Plaintiff, Barbara Earnest  
Trial Counsel for the PSC*

*Trial Counsel for the PSC*



/s/ Christopher L. Coffin

Christopher L. Coffin (#27902)  
PENDLEY, BAUDIN & COFFIN, L.L.P.  
1100 Poydras Street, Suite 2505  
New Orleans, Louisiana 70163  
Phone: (504) 355-0086  
Fax: (504) 355-0089  
[ccoffin@pbclawfirm.com](mailto:ccoffin@pbclawfirm.com)

*Plaintiffs' Co-Lead Counsel*

/s/M. Palmer Lambert

M. Palmer Lambert (#33228)  
GAINSBURGH BENJAMIN  
DAVID MEUNIER & WARSHAUER,  
LLC  
2800 Energy Centre, 1100 Poydras Street  
New Orleans, LA 70163-2800  
Phone: 504-522-2304  
Fax: 504-528-9973  
[plambert@gainsben.com](mailto:plambert@gainsben.com)

*Plaintiffs' Co-Liaison Counsel*

/s/ Karen B. Menzies

Karen Barth Menzies (CA Bar #180234)  
GIBBS LAW GROUP LLP  
6701 Center Drive West, Suite 1400  
Los Angeles, California 90045  
Telephone: 510-350-9700  
Facsimile: 510-350-9701  
[kbm@classlawgroup.com](mailto:kbm@classlawgroup.com)

*Plaintiffs' Co-Lead Counsel*

/s/Dawn M. Barrios

Dawn M. Barrios (#2821)  
BARRIOS, KINGSDORF & CASTEIX, LLP  
701 Poydras Street, Suite 3650  
New Orleans, LA 70139  
Phone: 504-524-3300  
Fax: 504-524-3313  
[barrios@bkc-law.com](mailto:barrios@bkc-law.com)

*Plaintiffs' Co-Liaison Counsel*

#### PLAINTIFFS' STEERING COMMITTEE

Anne Andrews  
Andrews & Thornton  
4701 Von Karman Ave., Suite 300  
Newport Beach, CA 92660  
Phone: (800) 664-1734  
[aa@andrewsthornton.com](mailto:aa@andrewsthornton.com)

Daniel P. Markoff  
Atkins & Markoff Law Firm  
9211 Lake Hefner Parkway, Suite 104  
Oklahoma City, OK 73120  
Phone: (405) 607-8757  
Fax: (405) 607-8749  
[dmarkoff@atkinsandmarkoff.com](mailto:dmarkoff@atkinsandmarkoff.com)

J. Kyle Bachus  
Bachus & Schanker, LLC  
1899 Wynkoop Street, Suite 700  
Denver, CO 80202  
Phone: (303) 893-9800  
Fax: (303) 893-9900  
[kyle.bachus@coloradolaw.net](mailto:kyle.bachus@coloradolaw.net)

Abby E. McClellan  
Stueve Siegel Hanson LLP  
460 Nichols Road, Suite 200  
Kansas City, MO 64112  
Phone: (816) 714-7100  
Fax: (816) 714-7101  
[mcclellan@stuevesiegel.com](mailto:mcclellan@stuevesiegel.com)

Lawrence J. Centola, III  
Martzell, Bickford & Centola  
338 Lafayette Street  
New Orleans, LA 70130  
Phone: (504) 581-9065  
Fax: (504) 581-7635  
[lcentola@mbfirm.com](mailto:lcentola@mbfirm.com)

Christopher L. Coffin  
Pendley, Baudin & Coffin, L.L.P.  
1100 Poydras Street, Suite 2505  
New Orleans, Louisiana 70163  
Phone: (504) 355-0086  
Fax: (504) 355-0089  
[ccoffin@pbclawfirm.com](mailto:ccoffin@pbclawfirm.com)

Alexander G. Dwyer  
Kirkendall Dwyer LLP  
440 Louisiana, Suite 1901  
Houston, TX 77002  
Phone: (713) 522-3529  
Fax: (713) 495-2331  
[adwyer@kirkendalldwyer.com](mailto:adwyer@kirkendalldwyer.com)

Emily C. Jeffcott  
Morgan & Morgan  
700 S. Palafox Street, Suite 95  
Pensacola, Florida 32505  
Phone: (850) 316-9074  
Fax: (850) 316-9079  
[ejeffcott@forthepeople.com](mailto:ejeffcott@forthepeople.com)

Andrew Lemmon  
Lemmon Law Firm, LLC  
P.O. Box 904  
15058 River Road  
Hahnville, LA 70057  
Phone: (985) 783-6789  
Fax: (985) 783-1333  
[andrew@lemmonlawfirm.com](mailto:andrew@lemmonlawfirm.com)

Karen Barth Menzies  
Gibbs Law Group LLP  
6701 Center Drive West, Suite 1400  
Los Angeles, California 90045  
Phone: 510-350-9700  
Fax: 510-350-9701  
[kbm@classlawgroup.com](mailto:kbm@classlawgroup.com)

David F. Miceli  
David F. Miceli, LLC  
P.O. Box 2519  
Carrollton, GA 30112  
Phone: (404) 915-8886  
[dmiceli@miceli-law.com](mailto:dmiceli@miceli-law.com)

Rand P. Nolen  
Fleming, Nolen & Jez, L.L.P.  
2800 Post Oak Blvd., Suite 4000  
Houston, TX 77056  
Phone: (713) 621-7944  
Fax: (713) 621-9638  
[rand\\_nolen@fleming-law.com](mailto:rand_nolen@fleming-law.com)

Hunter J. Shkolnik  
Napoli Shkolnik PLLC  
360 Lexington Avenue, 11<sup>th</sup> Floor  
New York, NY 10017  
Phone: (212) 397-1000  
[hunter@napolilaw.com](mailto:hunter@napolilaw.com)

Genevieve Zimmerman  
Meshbesh & Spence Ltd.  
1616 Park Avenue South  
Minneapolis, MN 55404  
Phone: (612) 339-9121  
Fax: (612) 339-9188  
[gzimmerman@meshbesh.com](mailto:gzimmerman@meshbesh.com)

**CERTIFICATE OF SERVICE**

I hereby certify that on July 16, 2019, I electronically filed the foregoing with the Clerk of Court by using the CM/ECF system which will send a notice of electronic filing to all counsel of record who are CM/ECF participants.

*/s/ M. Palmer Lambert*

M. PALMER LAMBERT